NASDAQ:STOK Stoke Therapeutics Q3 2026 Earnings Report $23.95 -0.34 (-1.40%) Closing price 04:00 PM EasternExtended Trading$24.12 +0.18 (+0.73%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Stoke Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.88Beat/MissN/AOne Year Ago EPSN/AStoke Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$8.21 millionBeat/MissN/AYoY Revenue GrowthN/AStoke Therapeutics Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Stoke Therapeutics Earnings HeadlinesStoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual MeetingOctober 6 at 2:15 PM | marketscreener.comMStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...October 6 at 2:15 PM | finance.yahoo.comOminous New Day in America (Get Ready for it)A market forecaster with a 55-year track record - including calls on 1970s double-digit inflation, the 1980s S&L collapse and Black Monday crash, and the 2000s dot-com bust and Lehman Brothers collapse - says a major shift is coming to how Americans bank, work and insure themselves. The New York Times has credited him as the first to spot looming dangers, and he has testified before Congress on past financial crises.October 8 at 1:00 AM | Weiss Ratings (Ad)Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingOctober 6 at 8:00 AM | businesswire.comStoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For ZorevunersenOctober 5 at 7:50 PM | marketscreener.comMStoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDAOctober 5 at 7:50 PM | finance.yahoo.comSee More Stoke Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email. Email Address About Stoke TherapeuticsStoke Therapeutics (NASDAQ:STOK) is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes. Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene. The company has also pursued additional TANGO-based programs for other genetic diseases, including conditions affecting the nervous system and vision. Founded in 2014 and headquartered in Bedford, Massachusetts, Stoke conducts research and clinical development activities through collaborations and clinical studies in the United States and other regions. The company is led by Edward Kaye, M.D., who serves as chief executive officer and has experience in the development of therapies for rare diseases.View Stoke Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
